 Thomas Campbell
Concepts (641)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 111 | 2024 | 2837 | 6.330 |
Why?
| | Sarcoma, Kaposi | 25 | 2025 | 81 | 6.120 |
Why?
| | HIV-1 | 61 | 2023 | 864 | 4.500 |
Why?
| | Anti-HIV Agents | 47 | 2024 | 778 | 3.980 |
Why?
| | Herpesvirus 8, Human | 22 | 2024 | 65 | 3.340 |
Why?
| | Antiretroviral Therapy, Highly Active | 30 | 2023 | 271 | 2.540 |
Why?
| | AIDS-Related Opportunistic Infections | 13 | 2024 | 127 | 1.820 |
Why?
| | Anti-Retroviral Agents | 21 | 2024 | 233 | 1.790 |
Why?
| | Viral Load | 34 | 2023 | 469 | 1.410 |
Why?
| | Acquired Immunodeficiency Syndrome | 7 | 2023 | 230 | 1.390 |
Why?
| | Zimbabwe | 18 | 2024 | 58 | 1.340 |
Why?
| | HIV Seropositivity | 7 | 2021 | 125 | 1.330 |
Why?
| | International Cooperation | 4 | 2018 | 198 | 1.170 |
Why?
| | Biomarkers, Tumor | 2 | 2025 | 1276 | 1.140 |
Why?
| | CD4 Lymphocyte Count | 26 | 2023 | 269 | 1.050 |
Why?
| | Inflammation | 16 | 2025 | 2838 | 1.030 |
Why?
| | Aging | 9 | 2024 | 1865 | 1.010 |
Why?
| | Education, Medical | 3 | 2018 | 266 | 0.980 |
Why?
| | alpha 1-Antichymotrypsin | 1 | 2025 | 4 | 0.930 |
Why?
| | RNA, Viral | 19 | 2014 | 656 | 0.870 |
Why?
| | Physical Fitness | 2 | 2015 | 209 | 0.820 |
Why?
| | Adult | 96 | 2025 | 38023 | 0.810 |
Why?
| | Middle Aged | 73 | 2025 | 33554 | 0.790 |
Why?
| | DNA, Viral | 12 | 2013 | 364 | 0.780 |
Why?
| | Humans | 162 | 2025 | 137782 | 0.780 |
Why?
| | Male | 114 | 2025 | 67906 | 0.770 |
Why?
| | Tuberculosis | 7 | 2023 | 279 | 0.760 |
Why?
| | Drug Resistance, Viral | 8 | 2015 | 116 | 0.730 |
Why?
| | Viremia | 6 | 2011 | 138 | 0.730 |
Why?
| | Herpesviridae Infections | 7 | 2021 | 147 | 0.720 |
Why?
| | Female | 108 | 2025 | 73465 | 0.720 |
Why?
| | Antibodies, Viral | 8 | 2023 | 628 | 0.700 |
Why?
| | AIDS Dementia Complex | 7 | 2015 | 51 | 0.680 |
Why?
| | Coinfection | 6 | 2019 | 137 | 0.670 |
Why?
| | CD4-Positive T-Lymphocytes | 12 | 2023 | 1091 | 0.670 |
Why?
| | Granulocyte Colony-Stimulating Factor | 4 | 2004 | 74 | 0.640 |
Why?
| | Reverse Transcriptase Inhibitors | 6 | 2015 | 84 | 0.630 |
Why?
| | Nursing Staff, Hospital | 1 | 2022 | 162 | 0.630 |
Why?
| | Lamivudine | 6 | 2017 | 63 | 0.620 |
Why?
| | Hematopoietic Stem Cell Mobilization | 3 | 2004 | 22 | 0.610 |
Why?
| | Lipopolysaccharide Receptors | 2 | 2021 | 85 | 0.610 |
Why?
| | Anemia | 3 | 2023 | 170 | 0.590 |
Why?
| | Vitamin D Deficiency | 3 | 2017 | 186 | 0.580 |
Why?
| | HIV | 8 | 2023 | 234 | 0.570 |
Why?
| | Vitamin D | 5 | 2018 | 397 | 0.560 |
Why?
| | Plasma | 4 | 2015 | 212 | 0.520 |
Why?
| | Micronutrients | 4 | 2018 | 92 | 0.510 |
Why?
| | 1-Alkyl-2-acetylglycerophosphocholine Esterase | 2 | 2023 | 22 | 0.510 |
Why?
| | Health Resources | 5 | 2019 | 121 | 0.500 |
Why?
| | Internationality | 5 | 2019 | 155 | 0.490 |
Why?
| | Gastrointestinal Microbiome | 5 | 2024 | 697 | 0.490 |
Why?
| | Breast Neoplasms | 2 | 2025 | 2253 | 0.480 |
Why?
| | Motor Activity | 3 | 2015 | 718 | 0.480 |
Why?
| | Prospective Studies | 21 | 2022 | 7623 | 0.470 |
Why?
| | RNA, Catalytic | 4 | 1997 | 187 | 0.470 |
Why?
| | Burnout, Professional | 1 | 2022 | 442 | 0.460 |
Why?
| | Awareness | 1 | 2015 | 103 | 0.460 |
Why?
| | Developing Countries | 10 | 2020 | 308 | 0.460 |
Why?
| | Benzoxazines | 6 | 2017 | 31 | 0.450 |
Why?
| | Antibiotics, Antineoplastic | 3 | 2023 | 128 | 0.450 |
Why?
| | Zidovudine | 7 | 2017 | 78 | 0.440 |
Why?
| | Quality of Life | 6 | 2019 | 2894 | 0.440 |
Why?
| | Lung Neoplasms | 2 | 2025 | 2526 | 0.430 |
Why?
| | HIV Integrase Inhibitors | 1 | 2015 | 70 | 0.430 |
Why?
| | C-Reactive Protein | 5 | 2015 | 410 | 0.420 |
Why?
| | Cytomegalovirus Infections | 1 | 2015 | 192 | 0.410 |
Why?
| | Bronchoalveolar Lavage Fluid | 6 | 2021 | 652 | 0.410 |
Why?
| | Monocytes | 2 | 2023 | 563 | 0.410 |
Why?
| | Immune Reconstitution Inflammatory Syndrome | 4 | 2020 | 18 | 0.390 |
Why?
| | Aged | 24 | 2025 | 24001 | 0.390 |
Why?
| | Biomarkers | 13 | 2023 | 4154 | 0.390 |
Why?
| | Treatment Outcome | 22 | 2023 | 10837 | 0.390 |
Why?
| | Disease Progression | 11 | 2025 | 2760 | 0.380 |
Why?
| | Sarcopenia | 1 | 2013 | 83 | 0.370 |
Why?
| | Receptors, CCR5 | 5 | 2021 | 56 | 0.370 |
Why?
| | Malnutrition | 3 | 2018 | 83 | 0.360 |
Why?
| | Case-Control Studies | 9 | 2025 | 3569 | 0.360 |
Why?
| | Homosexuality, Male | 4 | 2021 | 184 | 0.340 |
Why?
| | Faculty, Medical | 4 | 2018 | 283 | 0.340 |
Why?
| | South America | 7 | 2020 | 60 | 0.330 |
Why?
| | Osteoporosis | 1 | 2013 | 243 | 0.330 |
Why?
| | Africa | 6 | 2020 | 108 | 0.330 |
Why?
| | Accidental Falls | 1 | 2012 | 196 | 0.330 |
Why?
| | Neutropenia | 1 | 2010 | 146 | 0.320 |
Why?
| | Antiviral Agents | 5 | 2017 | 744 | 0.320 |
Why?
| | Antineoplastic Agents, Phytogenic | 3 | 2020 | 191 | 0.320 |
Why?
| | Virus Replication | 6 | 2006 | 483 | 0.320 |
Why?
| | Cross-Sectional Studies | 10 | 2022 | 5478 | 0.310 |
Why?
| | Tenofovir | 6 | 2017 | 243 | 0.310 |
Why?
| | Drug Therapy, Combination | 10 | 2020 | 1067 | 0.310 |
Why?
| | Sexual Behavior | 4 | 2020 | 485 | 0.310 |
Why?
| | Emergency Medical Services | 1 | 2015 | 552 | 0.310 |
Why?
| | Randomized Controlled Trials as Topic | 9 | 2025 | 1478 | 0.300 |
Why?
| | Advance Care Planning | 1 | 2012 | 209 | 0.300 |
Why?
| | Drug Monitoring | 1 | 2010 | 221 | 0.300 |
Why?
| | Thrombocytopenia | 1 | 2010 | 200 | 0.290 |
Why?
| | Viral Proteins | 2 | 2008 | 342 | 0.290 |
Why?
| | Health Services Accessibility | 1 | 2015 | 991 | 0.280 |
Why?
| | Genetic Variation | 4 | 2008 | 991 | 0.280 |
Why?
| | Pharmacogenetics | 3 | 2023 | 180 | 0.280 |
Why?
| | Sex Characteristics | 3 | 2023 | 763 | 0.280 |
Why?
| | Etoposide | 4 | 2023 | 158 | 0.270 |
Why?
| | Sexual and Gender Minorities | 3 | 2021 | 215 | 0.270 |
Why?
| | Microbiota | 4 | 2018 | 762 | 0.270 |
Why?
| | Professional Competence | 2 | 2018 | 100 | 0.270 |
Why?
| | Atazanavir Sulfate | 3 | 2016 | 41 | 0.270 |
Why?
| | Cohort Studies | 20 | 2019 | 5750 | 0.270 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2015 | 1330 | 0.270 |
Why?
| | Cyclopropanes | 6 | 2017 | 90 | 0.260 |
Why?
| | Alkynes | 6 | 2017 | 56 | 0.260 |
Why?
| | Schools, Medical | 2 | 2018 | 147 | 0.260 |
Why?
| | Survival Analysis | 4 | 2015 | 1325 | 0.260 |
Why?
| | Macrophages, Alveolar | 2 | 2020 | 391 | 0.250 |
Why?
| | Asia | 5 | 2016 | 71 | 0.250 |
Why?
| | CD8-Positive T-Lymphocytes | 4 | 2021 | 903 | 0.240 |
Why?
| | Sex Factors | 4 | 2016 | 2077 | 0.240 |
Why?
| | Needs Assessment | 2 | 2018 | 376 | 0.240 |
Why?
| | Treatment Failure | 8 | 2018 | 356 | 0.240 |
Why?
| | Risk Factors | 17 | 2024 | 10407 | 0.240 |
Why?
| | Drug Resistance, Multiple, Viral | 1 | 2005 | 10 | 0.240 |
Why?
| | Pregnancy Complications, Infectious | 3 | 2018 | 394 | 0.240 |
Why?
| | Genotype | 7 | 2023 | 1917 | 0.240 |
Why?
| | Young Adult | 19 | 2023 | 13240 | 0.240 |
Why?
| | Body Composition | 2 | 2020 | 684 | 0.230 |
Why?
| | Proportional Hazards Models | 7 | 2018 | 1266 | 0.230 |
Why?
| | Immune System Diseases | 1 | 2004 | 39 | 0.220 |
Why?
| | Salvage Therapy | 1 | 2005 | 142 | 0.220 |
Why?
| | Virus Latency | 1 | 2004 | 80 | 0.220 |
Why?
| | Lymph Nodes | 3 | 2011 | 491 | 0.220 |
Why?
| | Xenobiotics | 1 | 2024 | 32 | 0.210 |
Why?
| | Dideoxynucleosides | 2 | 2014 | 21 | 0.210 |
Why?
| | Curriculum | 4 | 2018 | 996 | 0.210 |
Why?
| | Cardiotoxicity | 1 | 2023 | 27 | 0.200 |
Why?
| | Program Evaluation | 2 | 2018 | 901 | 0.200 |
Why?
| | Insulin-Like Growth Factor I | 2 | 2017 | 319 | 0.200 |
Why?
| | Heart Injuries | 1 | 2023 | 37 | 0.200 |
Why?
| | Feces | 4 | 2021 | 484 | 0.200 |
Why?
| | Interleukin-10 | 2 | 2023 | 302 | 0.200 |
Why?
| | Intestinal Mucosa | 2 | 2021 | 623 | 0.190 |
Why?
| | ADP-ribosyl Cyclase 1 | 2 | 2013 | 38 | 0.190 |
Why?
| | Lung | 8 | 2022 | 4060 | 0.190 |
Why?
| | Prevalence | 9 | 2019 | 2734 | 0.190 |
Why?
| | Neurocognitive Disorders | 2 | 2019 | 26 | 0.190 |
Why?
| | Nevirapine | 2 | 2013 | 17 | 0.190 |
Why?
| | Plaque, Atherosclerotic | 1 | 2023 | 57 | 0.190 |
Why?
| | Incidence | 7 | 2023 | 2804 | 0.190 |
Why?
| | United States | 9 | 2023 | 14870 | 0.190 |
Why?
| | Myocarditis | 1 | 2023 | 100 | 0.190 |
Why?
| | Surveys and Questionnaires | 5 | 2022 | 5793 | 0.180 |
Why?
| | Research Design | 2 | 2025 | 1139 | 0.180 |
Why?
| | Personnel Turnover | 1 | 2022 | 40 | 0.180 |
Why?
| | Immunogenicity, Vaccine | 1 | 2021 | 30 | 0.180 |
Why?
| | Emtricitabine | 4 | 2017 | 175 | 0.180 |
Why?
| | Speech | 1 | 2022 | 70 | 0.180 |
Why?
| | Adolescent | 16 | 2023 | 21574 | 0.180 |
Why?
| | Polymerase Chain Reaction | 6 | 2021 | 1063 | 0.180 |
Why?
| | Lymphocytes | 2 | 2023 | 397 | 0.180 |
Why?
| | Amyotrophic Lateral Sclerosis | 1 | 2022 | 89 | 0.180 |
Why?
| | Gastrointestinal Tract | 2 | 2014 | 202 | 0.180 |
Why?
| | Cognition | 4 | 2017 | 1157 | 0.180 |
Why?
| | B-Cell Maturation Antigen | 1 | 2021 | 13 | 0.180 |
Why?
| | Selenium | 3 | 2018 | 43 | 0.180 |
Why?
| | Firmicutes | 1 | 2021 | 19 | 0.170 |
Why?
| | Doxorubicin | 1 | 2023 | 363 | 0.170 |
Why?
| | Multivariate Analysis | 4 | 2015 | 1509 | 0.170 |
Why?
| | Thinking | 1 | 2021 | 65 | 0.170 |
Why?
| | Longitudinal Studies | 9 | 2019 | 2860 | 0.170 |
Why?
| | Odds Ratio | 2 | 2014 | 1070 | 0.170 |
Why?
| | Filgrastim | 4 | 2004 | 8 | 0.170 |
Why?
| | T-Lymphocytopenia, Idiopathic CD4-Positive | 1 | 2020 | 7 | 0.160 |
Why?
| | Pilot Projects | 5 | 2014 | 1713 | 0.160 |
Why?
| | Intention | 1 | 2022 | 170 | 0.160 |
Why?
| | Leukapheresis | 1 | 2000 | 21 | 0.160 |
Why?
| | Pyridazines | 2 | 2012 | 56 | 0.160 |
Why?
| | Leadership | 3 | 2018 | 388 | 0.160 |
Why?
| | Workplace | 1 | 2022 | 261 | 0.160 |
Why?
| | Hematopoietic Stem Cells | 2 | 2000 | 406 | 0.160 |
Why?
| | Vincristine | 1 | 2020 | 116 | 0.160 |
Why?
| | Job Satisfaction | 1 | 2022 | 218 | 0.160 |
Why?
| | Membrane Glycoproteins | 2 | 2013 | 500 | 0.160 |
Why?
| | Weight Loss | 3 | 2020 | 788 | 0.160 |
Why?
| | Bacteria | 3 | 2018 | 858 | 0.150 |
Why?
| | Germ-Free Life | 1 | 2019 | 34 | 0.150 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2020 | 128 | 0.150 |
Why?
| | B-Lymphocytes | 1 | 2004 | 847 | 0.150 |
Why?
| | Epigenesis, Genetic | 1 | 2024 | 660 | 0.150 |
Why?
| | Hexosaminidases | 1 | 2019 | 18 | 0.150 |
Why?
| | Exercise | 2 | 2021 | 2061 | 0.150 |
Why?
| | Prevotella | 1 | 2018 | 14 | 0.150 |
Why?
| | Brain | 4 | 2019 | 2677 | 0.150 |
Why?
| | Clinical Trials as Topic | 2 | 2016 | 1052 | 0.150 |
Why?
| | DNA Methylation | 1 | 2024 | 643 | 0.150 |
Why?
| | Violence | 1 | 2022 | 267 | 0.150 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2021 | 388 | 0.150 |
Why?
| | Basal Ganglia | 3 | 2014 | 56 | 0.150 |
Why?
| | Suicide | 2 | 2017 | 657 | 0.150 |
Why?
| | Atherosclerosis | 1 | 2023 | 415 | 0.150 |
Why?
| | Bleomycin | 1 | 2020 | 248 | 0.150 |
Why?
| | Cerebral Cortex | 2 | 2013 | 433 | 0.150 |
Why?
| | Organophosphonates | 3 | 2013 | 93 | 0.140 |
Why?
| | Urban Population | 2 | 2013 | 479 | 0.140 |
Why?
| | Genes, pol | 3 | 2007 | 7 | 0.140 |
Why?
| | Mouth | 2 | 2015 | 87 | 0.140 |
Why?
| | Mutation | 5 | 2016 | 3959 | 0.140 |
Why?
| | AIDS Vaccines | 1 | 2018 | 52 | 0.140 |
Why?
| | Proteomics | 1 | 2025 | 1111 | 0.140 |
Why?
| | Multiple Myeloma | 1 | 2021 | 252 | 0.140 |
Why?
| | Drug Combinations | 2 | 2017 | 343 | 0.140 |
Why?
| | Capacity Building | 1 | 2018 | 63 | 0.140 |
Why?
| | HIV Protease Inhibitors | 2 | 2016 | 69 | 0.140 |
Why?
| | Vitamin A Deficiency | 1 | 2017 | 26 | 0.140 |
Why?
| | Early Detection of Cancer | 1 | 2022 | 448 | 0.140 |
Why?
| | Brain Injuries, Traumatic | 1 | 2023 | 372 | 0.140 |
Why?
| | Nucleic Acid Conformation | 2 | 1997 | 728 | 0.130 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2017 | 92 | 0.130 |
Why?
| | Immunotherapy, Adoptive | 1 | 2021 | 332 | 0.130 |
Why?
| | Didanosine | 2 | 2014 | 13 | 0.130 |
Why?
| | Follow-Up Studies | 7 | 2021 | 5136 | 0.130 |
Why?
| | Herpesvirus 2, Human | 1 | 2017 | 29 | 0.130 |
Why?
| | Inflammation Mediators | 2 | 2018 | 513 | 0.130 |
Why?
| | Financing, Organized | 1 | 2017 | 35 | 0.130 |
Why?
| | Dysbiosis | 2 | 2021 | 181 | 0.130 |
Why?
| | Adenine | 3 | 2013 | 271 | 0.130 |
Why?
| | Anti-Inflammatory Agents | 1 | 2020 | 496 | 0.130 |
Why?
| | Hospitals | 1 | 2022 | 691 | 0.130 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2017 | 201 | 0.130 |
Why?
| | Cognitive Dysfunction | 2 | 2019 | 383 | 0.130 |
Why?
| | Recombinant Proteins | 4 | 2004 | 1356 | 0.130 |
Why?
| | Africa South of the Sahara | 4 | 2020 | 48 | 0.130 |
Why?
| | Haiti | 2 | 2016 | 11 | 0.130 |
Why?
| | Coronary Artery Disease | 1 | 2023 | 698 | 0.130 |
Why?
| | Kaplan-Meier Estimate | 3 | 2013 | 889 | 0.130 |
Why?
| | Genes, env | 2 | 2007 | 5 | 0.130 |
Why?
| | Herpes Simplex | 1 | 2017 | 95 | 0.130 |
Why?
| | Magnetic Resonance Spectroscopy | 3 | 2014 | 611 | 0.120 |
Why?
| | Immunoglobulin G | 2 | 2023 | 893 | 0.120 |
Why?
| | Nervous System Diseases | 1 | 2019 | 266 | 0.120 |
Why?
| | Tetrahymena thermophila | 1 | 1996 | 65 | 0.120 |
Why?
| | Lymphocyte Activation | 3 | 2018 | 1142 | 0.120 |
Why?
| | Military Personnel | 1 | 2023 | 549 | 0.120 |
Why?
| | Ghana | 1 | 2015 | 38 | 0.120 |
Why?
| | Mental Status and Dementia Tests | 1 | 2016 | 26 | 0.120 |
Why?
| | Up-Regulation | 1 | 2019 | 843 | 0.120 |
Why?
| | Pregnancy Outcome | 1 | 2018 | 416 | 0.120 |
Why?
| | Molecular Sequence Data | 6 | 2013 | 2900 | 0.120 |
Why?
| | Ambulances | 1 | 2015 | 51 | 0.120 |
Why?
| | Muscle Strength | 1 | 2018 | 322 | 0.120 |
Why?
| | TRPP Cation Channels | 1 | 2016 | 85 | 0.120 |
Why?
| | DNA, Protozoan | 1 | 2015 | 32 | 0.120 |
Why?
| | RNA, Protozoan | 1 | 1995 | 60 | 0.120 |
Why?
| | Hepatitis B, Chronic | 1 | 2015 | 23 | 0.120 |
Why?
| | Liver | 1 | 2024 | 1943 | 0.120 |
Why?
| | Plasmodium falciparum | 1 | 2015 | 30 | 0.120 |
Why?
| | Clinical Competence | 2 | 2021 | 1129 | 0.120 |
Why?
| | Rhodobacter sphaeroides | 3 | 1983 | 7 | 0.110 |
Why?
| | Chemokine CXCL10 | 1 | 2015 | 39 | 0.110 |
Why?
| | Cerebrospinal Fluid | 1 | 2015 | 92 | 0.110 |
Why?
| | Malaria | 1 | 2015 | 63 | 0.110 |
Why?
| | Research | 1 | 2018 | 451 | 0.110 |
Why?
| | Retroviridae Infections | 1 | 1995 | 47 | 0.110 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2015 | 135 | 0.110 |
Why?
| | Anthracyclines | 1 | 2014 | 42 | 0.110 |
Why?
| | Cytomegalovirus | 1 | 2015 | 157 | 0.110 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2017 | 213 | 0.110 |
Why?
| | Time Factors | 3 | 2015 | 6834 | 0.110 |
Why?
| | Health Occupations | 1 | 2014 | 34 | 0.110 |
Why?
| | Orchitis | 1 | 2014 | 5 | 0.110 |
Why?
| | Penicillin G | 1 | 2014 | 7 | 0.110 |
Why?
| | Caribbean Region | 2 | 2011 | 28 | 0.110 |
Why?
| | Exercise Therapy | 1 | 2018 | 443 | 0.110 |
Why?
| | Phylogeny | 3 | 2008 | 904 | 0.110 |
Why?
| | Health Care Surveys | 1 | 2015 | 565 | 0.110 |
Why?
| | Syphilis | 1 | 2014 | 32 | 0.100 |
Why?
| | Stavudine | 1 | 2013 | 8 | 0.100 |
Why?
| | Tropheryma | 1 | 2013 | 5 | 0.100 |
Why?
| | Seroepidemiologic Studies | 2 | 2015 | 165 | 0.100 |
Why?
| | Aging, Premature | 1 | 2013 | 13 | 0.100 |
Why?
| | Whipple Disease | 1 | 2013 | 6 | 0.100 |
Why?
| | Metabolic Diseases | 1 | 2014 | 108 | 0.100 |
Why?
| | Biota | 1 | 2013 | 34 | 0.100 |
Why?
| | Education, Medical, Graduate | 1 | 2018 | 486 | 0.100 |
Why?
| | HIV Antigens | 3 | 2015 | 18 | 0.100 |
Why?
| | Pyrrolidinones | 1 | 2013 | 28 | 0.100 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 1 | 2013 | 39 | 0.100 |
Why?
| | Genitalia, Male | 1 | 2013 | 11 | 0.100 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 445 | 0.100 |
Why?
| | Body Fat Distribution | 1 | 2013 | 49 | 0.100 |
Why?
| | Infectious Disease Transmission, Vertical | 2 | 2012 | 184 | 0.100 |
Why?
| | Problem-Based Learning | 1 | 2014 | 92 | 0.100 |
Why?
| | Retinal Detachment | 1 | 2014 | 63 | 0.100 |
Why?
| | Peptide Fragments | 3 | 2007 | 706 | 0.100 |
Why?
| | Genitalia, Female | 1 | 2013 | 38 | 0.100 |
Why?
| | Hospitals, University | 1 | 2013 | 182 | 0.100 |
Why?
| | Genetic Therapy | 1 | 1995 | 297 | 0.100 |
Why?
| | Sequence Analysis, DNA | 3 | 2013 | 812 | 0.100 |
Why?
| | Fever | 2 | 2021 | 306 | 0.100 |
Why?
| | Pregnancy | 5 | 2018 | 6771 | 0.100 |
Why?
| | Suicidal Ideation | 2 | 2017 | 534 | 0.100 |
Why?
| | Metagenome | 1 | 2013 | 147 | 0.100 |
Why?
| | Weight Gain | 1 | 2016 | 519 | 0.090 |
Why?
| | RNA Stability | 1 | 2013 | 117 | 0.090 |
Why?
| | Frail Elderly | 1 | 2013 | 131 | 0.090 |
Why?
| | Hepatitis B | 1 | 2013 | 70 | 0.090 |
Why?
| | Aspergillosis | 1 | 1992 | 21 | 0.090 |
Why?
| | Prostatitis | 1 | 1992 | 18 | 0.090 |
Why?
| | Muscles | 1 | 2013 | 326 | 0.090 |
Why?
| | Urinary Catheterization | 1 | 1992 | 33 | 0.090 |
Why?
| | Movement | 1 | 2014 | 278 | 0.090 |
Why?
| | Withholding Treatment | 1 | 2012 | 76 | 0.090 |
Why?
| | Respiratory System | 1 | 2013 | 157 | 0.090 |
Why?
| | Universities | 1 | 2014 | 433 | 0.090 |
Why?
| | Marijuana Smoking | 1 | 2015 | 256 | 0.090 |
Why?
| | Unsafe Sex | 1 | 2012 | 60 | 0.090 |
Why?
| | Catheters, Indwelling | 1 | 1992 | 91 | 0.090 |
Why?
| | HIV Core Protein p24 | 3 | 2006 | 31 | 0.090 |
Why?
| | Body Weight | 1 | 2016 | 985 | 0.090 |
Why?
| | Confidence Intervals | 1 | 2012 | 329 | 0.090 |
Why?
| | Education, Medical, Undergraduate | 1 | 2014 | 188 | 0.090 |
Why?
| | Neuropsychological Tests | 4 | 2019 | 1025 | 0.090 |
Why?
| | Exanthema | 1 | 2012 | 78 | 0.090 |
Why?
| | Paclitaxel | 2 | 2020 | 230 | 0.090 |
Why?
| | Lipopolysaccharides | 1 | 2015 | 886 | 0.090 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2022 | 1242 | 0.090 |
Why?
| | Mycobacterium tuberculosis | 2 | 2012 | 314 | 0.090 |
Why?
| | CD4 Antigens | 1 | 2011 | 141 | 0.090 |
Why?
| | Polyneuropathies | 1 | 2011 | 55 | 0.090 |
Why?
| | Veterans | 1 | 2023 | 1479 | 0.090 |
Why?
| | Piperazines | 1 | 1993 | 350 | 0.090 |
Why?
| | Corpus Callosum | 1 | 2011 | 71 | 0.090 |
Why?
| | Americas | 1 | 2010 | 28 | 0.090 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2019 | 1042 | 0.090 |
Why?
| | Endothelial Cells | 2 | 2024 | 785 | 0.080 |
Why?
| | Body Mass Index | 3 | 2014 | 2390 | 0.080 |
Why?
| | Kidney Diseases | 1 | 2014 | 408 | 0.080 |
Why?
| | T-Lymphocyte Subsets | 2 | 2011 | 417 | 0.080 |
Why?
| | HLA-DR Antigens | 1 | 2011 | 228 | 0.080 |
Why?
| | RNA, Ribosomal, 16S | 3 | 2019 | 549 | 0.080 |
Why?
| | Smoking | 2 | 2020 | 1627 | 0.080 |
Why?
| | Bone and Bones | 1 | 2013 | 317 | 0.080 |
Why?
| | Patient Compliance | 1 | 2014 | 581 | 0.080 |
Why?
| | Specimen Handling | 1 | 2011 | 183 | 0.080 |
Why?
| | Fluorescent Antibody Technique | 3 | 2015 | 390 | 0.080 |
Why?
| | Antigens, Viral | 2 | 2021 | 178 | 0.080 |
Why?
| | HIV Reverse Transcriptase | 2 | 2004 | 31 | 0.080 |
Why?
| | Interleukin-6 | 3 | 2022 | 778 | 0.080 |
Why?
| | HIV Fusion Inhibitors | 2 | 2007 | 3 | 0.080 |
Why?
| | HIV Envelope Protein gp41 | 2 | 2007 | 11 | 0.080 |
Why?
| | Emigrants and Immigrants | 1 | 2012 | 136 | 0.080 |
Why?
| | Health Personnel | 1 | 2016 | 711 | 0.080 |
Why?
| | Bone Density | 1 | 2013 | 489 | 0.080 |
Why?
| | Tuberculosis, Pulmonary | 2 | 2013 | 141 | 0.080 |
Why?
| | Neuroimaging | 1 | 2011 | 260 | 0.080 |
Why?
| | Metabolic Syndrome | 1 | 2012 | 354 | 0.070 |
Why?
| | Smokers | 2 | 2020 | 145 | 0.070 |
Why?
| | RNA | 1 | 1995 | 921 | 0.070 |
Why?
| | South Africa | 3 | 2016 | 222 | 0.070 |
Why?
| | Lung Diseases | 1 | 2015 | 767 | 0.070 |
Why?
| | Uganda | 1 | 2008 | 77 | 0.070 |
Why?
| | Epitopes, T-Lymphocyte | 2 | 2006 | 181 | 0.070 |
Why?
| | Leukocytes, Mononuclear | 2 | 2021 | 558 | 0.070 |
Why?
| | Socioeconomic Factors | 1 | 2012 | 1290 | 0.070 |
Why?
| | Cytokines | 3 | 2021 | 2085 | 0.070 |
Why?
| | Base Composition | 2 | 1997 | 78 | 0.070 |
Why?
| | Sweating | 1 | 2007 | 40 | 0.070 |
Why?
| | Organizational Culture | 2 | 2018 | 152 | 0.060 |
Why?
| | Amino Acid Sequence | 3 | 2006 | 2139 | 0.060 |
Why?
| | Blood Vessels | 1 | 2008 | 187 | 0.060 |
Why?
| | Vitamin A | 2 | 2018 | 58 | 0.060 |
Why?
| | Healthy Volunteers | 2 | 2018 | 199 | 0.060 |
Why?
| | Colorado | 3 | 2012 | 4576 | 0.060 |
Why?
| | Purine Nucleosides | 1 | 2006 | 3 | 0.060 |
Why?
| | Gender Identity | 1 | 2007 | 124 | 0.060 |
Why?
| | Dioxolanes | 1 | 2006 | 6 | 0.060 |
Why?
| | Peru | 2 | 2016 | 58 | 0.060 |
Why?
| | Gene Products, gag | 1 | 2006 | 36 | 0.060 |
Why?
| | Substrate Specificity | 2 | 1997 | 372 | 0.060 |
Why?
| | Retrospective Studies | 4 | 2023 | 15682 | 0.060 |
Why?
| | Program Development | 2 | 2018 | 368 | 0.060 |
Why?
| | DNA, Bacterial | 3 | 2019 | 337 | 0.060 |
Why?
| | Phospholipids | 3 | 1983 | 223 | 0.060 |
Why?
| | Biopsy | 2 | 2020 | 1130 | 0.060 |
Why?
| | Logistic Models | 3 | 2015 | 2075 | 0.060 |
Why?
| | Selection Bias | 1 | 2005 | 37 | 0.060 |
Why?
| | Dizziness | 2 | 2018 | 82 | 0.060 |
Why?
| | Disease Reservoirs | 1 | 2004 | 21 | 0.060 |
Why?
| | Hypoalbuminemia | 1 | 2024 | 30 | 0.060 |
Why?
| | HIV Protease | 1 | 2004 | 4 | 0.060 |
Why?
| | Hepatocyte Nuclear Factor 4 | 1 | 2024 | 15 | 0.050 |
Why?
| | Multidrug Resistance-Associated Proteins | 1 | 2024 | 38 | 0.050 |
Why?
| | HIV Envelope Protein gp120 | 1 | 2004 | 60 | 0.050 |
Why?
| | Double-Blind Method | 3 | 2018 | 1997 | 0.050 |
Why?
| | Comorbidity | 1 | 2009 | 1623 | 0.050 |
Why?
| | Linear Models | 3 | 2011 | 849 | 0.050 |
Why?
| | CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2024 | 22 | 0.050 |
Why?
| | WT1 Proteins | 1 | 2024 | 15 | 0.050 |
Why?
| | Base Sequence | 3 | 1996 | 2181 | 0.050 |
Why?
| | Syndrome | 1 | 2004 | 358 | 0.050 |
Why?
| | Animals | 7 | 2024 | 36951 | 0.050 |
Why?
| | Castleman Disease | 1 | 2003 | 13 | 0.050 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2023 | 56 | 0.050 |
Why?
| | Aspartic Acid | 2 | 2014 | 79 | 0.050 |
Why?
| | Anti-Bacterial Agents | 1 | 2014 | 1809 | 0.050 |
Why?
| | Glucuronosyltransferase | 1 | 2023 | 16 | 0.050 |
Why?
| | Endemic Diseases | 1 | 2003 | 32 | 0.050 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2023 | 164 | 0.050 |
Why?
| | Reference Values | 2 | 2016 | 816 | 0.050 |
Why?
| | United Kingdom | 2 | 2014 | 318 | 0.050 |
Why?
| | Speech Intelligibility | 1 | 2022 | 5 | 0.050 |
Why?
| | Speech Production Measurement | 1 | 2022 | 12 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2023 | 2189 | 0.050 |
Why?
| | Binding Sites | 2 | 1996 | 1303 | 0.050 |
Why?
| | Choline | 2 | 2014 | 127 | 0.050 |
Why?
| | Lip | 1 | 2022 | 24 | 0.050 |
Why?
| | Interferon-gamma | 1 | 2006 | 789 | 0.050 |
Why?
| | Jaw | 1 | 2022 | 26 | 0.050 |
Why?
| | Protein Isoforms | 1 | 2024 | 404 | 0.050 |
Why?
| | Lopinavir | 2 | 2013 | 30 | 0.050 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 976 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 2 | 2011 | 3577 | 0.050 |
Why?
| | Tongue | 1 | 2022 | 81 | 0.050 |
Why?
| | Chemoradiotherapy | 1 | 2023 | 225 | 0.050 |
Why?
| | Deoxycytidine | 2 | 2014 | 179 | 0.050 |
Why?
| | Intention to Treat Analysis | 1 | 2021 | 73 | 0.050 |
Why?
| | Ritonavir | 2 | 2013 | 74 | 0.050 |
Why?
| | Patient Acuity | 1 | 2021 | 47 | 0.040 |
Why?
| | Ligands | 1 | 2023 | 664 | 0.040 |
Why?
| | Frontal Lobe | 2 | 2014 | 149 | 0.040 |
Why?
| | Immunization, Secondary | 1 | 2021 | 87 | 0.040 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 1 | 2021 | 43 | 0.040 |
Why?
| | Vidarabine | 1 | 2021 | 33 | 0.040 |
Why?
| | Hemoglobins | 1 | 2023 | 353 | 0.040 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2001 | 173 | 0.040 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2021 | 87 | 0.040 |
Why?
| | Cardiovascular Diseases | 1 | 2013 | 2111 | 0.040 |
Why?
| | Reproducibility of Results | 3 | 2008 | 3290 | 0.040 |
Why?
| | Antibodies, Neutralizing | 1 | 2023 | 286 | 0.040 |
Why?
| | Regression Analysis | 2 | 2014 | 1024 | 0.040 |
Why?
| | Single-Blind Method | 1 | 2021 | 282 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2023 | 545 | 0.040 |
Why?
| | Cyclophosphamide | 1 | 2021 | 247 | 0.040 |
Why?
| | Cell Line | 3 | 2001 | 2847 | 0.040 |
Why?
| | Integrin alpha Chains | 1 | 2020 | 24 | 0.040 |
Why?
| | Sensitivity and Specificity | 2 | 2007 | 1946 | 0.040 |
Why?
| | Cells, Cultured | 4 | 2008 | 4193 | 0.040 |
Why?
| | Cough | 1 | 2021 | 122 | 0.040 |
Why?
| | Echocardiography | 1 | 2023 | 644 | 0.040 |
Why?
| | Antigens, CD34 | 1 | 2000 | 88 | 0.040 |
Why?
| | Genome, Bacterial | 1 | 2021 | 142 | 0.040 |
Why?
| | Fatty Acids | 1 | 1983 | 443 | 0.040 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 853 | 0.040 |
Why?
| | Virion | 1 | 2000 | 93 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2024 | 676 | 0.040 |
Why?
| | Brazil | 2 | 2016 | 167 | 0.040 |
Why?
| | Immunologic Memory | 1 | 2001 | 353 | 0.040 |
Why?
| | Immunophenotyping | 1 | 2020 | 318 | 0.040 |
Why?
| | Nitriles | 2 | 2012 | 172 | 0.040 |
Why?
| | Biomechanical Phenomena | 1 | 2022 | 811 | 0.040 |
Why?
| | Diffusion Tensor Imaging | 1 | 2019 | 79 | 0.040 |
Why?
| | Teacher Training | 1 | 2018 | 6 | 0.040 |
Why?
| | Atrophy | 1 | 2019 | 184 | 0.040 |
Why?
| | Motor Skills | 1 | 2019 | 97 | 0.040 |
Why?
| | Genes, vpr | 1 | 1997 | 1 | 0.040 |
Why?
| | Genes, vif | 1 | 1997 | 3 | 0.040 |
Why?
| | Aspartate Aminotransferases | 1 | 2018 | 90 | 0.040 |
Why?
| | Trace Elements | 1 | 2018 | 51 | 0.040 |
Why?
| | Colony Count, Microbial | 1 | 2018 | 120 | 0.040 |
Why?
| | Back Pain | 1 | 2018 | 51 | 0.040 |
Why?
| | Stillbirth | 1 | 2018 | 72 | 0.030 |
Why?
| | Cytochrome P-450 CYP2B6 | 1 | 2017 | 9 | 0.030 |
Why?
| | Macaca mulatta | 1 | 2018 | 166 | 0.030 |
Why?
| | DNA Primers | 2 | 1996 | 516 | 0.030 |
Why?
| | Cytochrome P-450 CYP2A6 | 1 | 2017 | 11 | 0.030 |
Why?
| | Adenoviridae | 1 | 2018 | 193 | 0.030 |
Why?
| | Immunity, Humoral | 1 | 2018 | 116 | 0.030 |
Why?
| | Principal Component Analysis | 1 | 2018 | 195 | 0.030 |
Why?
| | Colon | 1 | 2020 | 282 | 0.030 |
Why?
| | Diarrhea | 1 | 2018 | 184 | 0.030 |
Why?
| | In Vitro Techniques | 1 | 2019 | 1092 | 0.030 |
Why?
| | Genome-Wide Association Study | 1 | 2024 | 1431 | 0.030 |
Why?
| | Toll-Like Receptors | 1 | 2018 | 185 | 0.030 |
Why?
| | Abdominal Pain | 1 | 2018 | 145 | 0.030 |
Why?
| | Genetic Vectors | 1 | 2018 | 319 | 0.030 |
Why?
| | Antigens, CD | 1 | 2020 | 521 | 0.030 |
Why?
| | Seroconversion | 1 | 2017 | 46 | 0.030 |
Why?
| | Oligoribonucleotides | 1 | 1996 | 52 | 0.030 |
Why?
| | Benzoxazoles | 1 | 1996 | 19 | 0.030 |
Why?
| | Immunity, Cellular | 1 | 2018 | 268 | 0.030 |
Why?
| | Ruthenium Red | 1 | 2016 | 7 | 0.030 |
Why?
| | Amiloride | 1 | 2016 | 26 | 0.030 |
Why?
| | Thailand | 1 | 2016 | 17 | 0.030 |
Why?
| | Pyrimidines | 2 | 2012 | 471 | 0.030 |
Why?
| | Gene Frequency | 1 | 2017 | 521 | 0.030 |
Why?
| | Fatigue | 1 | 2018 | 329 | 0.030 |
Why?
| | Malawi | 1 | 2016 | 53 | 0.030 |
Why?
| | Life Style | 1 | 2018 | 491 | 0.030 |
Why?
| | Administration, Oral | 1 | 2018 | 816 | 0.030 |
Why?
| | Immunosuppressive Agents | 1 | 2021 | 894 | 0.030 |
Why?
| | Patient Selection | 1 | 2000 | 696 | 0.030 |
Why?
| | India | 1 | 2016 | 195 | 0.030 |
Why?
| | Catalysis | 1 | 1996 | 307 | 0.030 |
Why?
| | Verbal Learning | 1 | 2016 | 60 | 0.030 |
Why?
| | Age Factors | 2 | 2016 | 3305 | 0.030 |
Why?
| | Parasitemia | 1 | 2015 | 13 | 0.030 |
Why?
| | Human Activities | 1 | 2015 | 21 | 0.030 |
Why?
| | Nutritional Status | 1 | 2018 | 350 | 0.030 |
Why?
| | pol Gene Products, Human Immunodeficiency Virus | 1 | 2015 | 1 | 0.030 |
Why?
| | Hepatitis B virus | 1 | 2015 | 40 | 0.030 |
Why?
| | Point Mutation | 1 | 2016 | 235 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2016 | 327 | 0.030 |
Why?
| | Tetrahymena | 1 | 1995 | 157 | 0.030 |
Why?
| | Carotenoids | 1 | 2015 | 43 | 0.030 |
Why?
| | Placebos | 1 | 2015 | 199 | 0.030 |
Why?
| | Genotyping Techniques | 1 | 2015 | 75 | 0.030 |
Why?
| | Pyridones | 1 | 1996 | 168 | 0.030 |
Why?
| | RNA Splicing | 1 | 1996 | 269 | 0.030 |
Why?
| | Nuclear Proteins | 1 | 1999 | 712 | 0.030 |
Why?
| | Chronic Disease | 2 | 2014 | 1794 | 0.030 |
Why?
| | Premature Birth | 1 | 2018 | 333 | 0.030 |
Why?
| | Vaccination | 1 | 2023 | 1381 | 0.030 |
Why?
| | Vitamin E | 1 | 2015 | 124 | 0.030 |
Why?
| | Fellowships and Scholarships | 1 | 2018 | 307 | 0.030 |
Why?
| | Schools, Health Occupations | 1 | 2014 | 8 | 0.030 |
Why?
| | Mice | 2 | 2024 | 17794 | 0.030 |
Why?
| | Retreatment | 1 | 2014 | 72 | 0.030 |
Why?
| | World Health Organization | 1 | 2014 | 123 | 0.030 |
Why?
| | Developed Countries | 1 | 2014 | 39 | 0.030 |
Why?
| | Genetic Markers | 1 | 2015 | 344 | 0.030 |
Why?
| | Ophthalmoscopy | 1 | 2014 | 36 | 0.030 |
Why?
| | Creatine | 1 | 2014 | 57 | 0.030 |
Why?
| | Psychology | 1 | 2014 | 85 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2018 | 2057 | 0.030 |
Why?
| | Diffusion of Innovation | 1 | 2014 | 100 | 0.030 |
Why?
| | Protons | 1 | 2014 | 89 | 0.030 |
Why?
| | Group Processes | 1 | 2014 | 64 | 0.030 |
Why?
| | Raltegravir Potassium | 1 | 2013 | 17 | 0.030 |
Why?
| | DNA, Ribosomal | 1 | 2013 | 88 | 0.030 |
Why?
| | Gray Matter | 1 | 2014 | 80 | 0.030 |
Why?
| | Skin | 1 | 2018 | 752 | 0.030 |
Why?
| | Educational Status | 1 | 2016 | 470 | 0.030 |
Why?
| | Inositol | 1 | 2013 | 26 | 0.030 |
Why?
| | Bronchoalveolar Lavage | 1 | 2013 | 93 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2024 | 5764 | 0.030 |
Why?
| | Hepatitis B Surface Antigens | 1 | 2013 | 24 | 0.030 |
Why?
| | Medication Adherence | 1 | 2017 | 467 | 0.030 |
Why?
| | Kinetics | 1 | 1996 | 1670 | 0.020 |
Why?
| | Phenotype | 2 | 2014 | 3196 | 0.020 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2015 | 249 | 0.020 |
Why?
| | Oligopeptides | 1 | 2014 | 271 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2016 | 660 | 0.020 |
Why?
| | Global Health | 1 | 2015 | 386 | 0.020 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 1 | 2016 | 262 | 0.020 |
Why?
| | Risk | 1 | 2015 | 912 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2015 | 430 | 0.020 |
Why?
| | Gene Expression Regulation | 2 | 2014 | 2607 | 0.020 |
Why?
| | Neurologic Examination | 1 | 2012 | 110 | 0.020 |
Why?
| | Microbial Sensitivity Tests | 1 | 1993 | 361 | 0.020 |
Why?
| | White Matter | 1 | 2014 | 145 | 0.020 |
Why?
| | Cause of Death | 1 | 2014 | 436 | 0.020 |
Why?
| | Hypertension, Pulmonary | 1 | 2003 | 1910 | 0.020 |
Why?
| | Kidney Failure, Chronic | 1 | 2017 | 570 | 0.020 |
Why?
| | Receptors, HIV | 1 | 2011 | 24 | 0.020 |
Why?
| | Blood Coagulation | 1 | 2013 | 257 | 0.020 |
Why?
| | Zebrafish | 1 | 2016 | 499 | 0.020 |
Why?
| | Visual Acuity | 1 | 2014 | 356 | 0.020 |
Why?
| | Psychological Tests | 1 | 2012 | 140 | 0.020 |
Why?
| | Headache | 1 | 2012 | 147 | 0.020 |
Why?
| | Glutamic Acid | 1 | 2013 | 246 | 0.020 |
Why?
| | Cooperative Behavior | 1 | 2014 | 452 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2015 | 1178 | 0.020 |
Why?
| | Data Collection | 1 | 2014 | 673 | 0.020 |
Why?
| | Hospitalization | 1 | 2021 | 2200 | 0.020 |
Why?
| | Pyridines | 1 | 2014 | 506 | 0.020 |
Why?
| | Mood Disorders | 1 | 2012 | 133 | 0.020 |
Why?
| | Biological Specimen Banks | 1 | 2011 | 102 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 1692 | 0.020 |
Why?
| | Models, Theoretical | 1 | 2014 | 578 | 0.020 |
Why?
| | Suicide, Attempted | 1 | 2014 | 382 | 0.020 |
Why?
| | Mozambique | 1 | 2010 | 7 | 0.020 |
Why?
| | Social Support | 1 | 2014 | 624 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2014 | 963 | 0.020 |
Why?
| | Calcium | 1 | 2016 | 1200 | 0.020 |
Why?
| | North America | 1 | 2011 | 313 | 0.020 |
Why?
| | Pyrimidinones | 1 | 2010 | 113 | 0.020 |
Why?
| | Antitubercular Agents | 1 | 2011 | 206 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2010 | 431 | 0.020 |
Why?
| | Gene Expression | 1 | 1995 | 1502 | 0.020 |
Why?
| | Neuroglia | 1 | 2010 | 173 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2018 | 1998 | 0.020 |
Why?
| | Thalamus | 1 | 2010 | 107 | 0.020 |
Why?
| | Multicenter Studies as Topic | 1 | 2010 | 310 | 0.020 |
Why?
| | Students, Medical | 1 | 2014 | 348 | 0.020 |
Why?
| | Organ Size | 1 | 2010 | 477 | 0.020 |
Why?
| | Mental Health | 1 | 2015 | 729 | 0.020 |
Why?
| | Caspase 7 | 1 | 2008 | 22 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2014 | 2041 | 0.020 |
Why?
| | In Situ Nick-End Labeling | 1 | 2008 | 124 | 0.020 |
Why?
| | Sleep Wake Disorders | 1 | 2012 | 290 | 0.020 |
Why?
| | Bone Morphogenetic Protein 4 | 1 | 2008 | 43 | 0.020 |
Why?
| | Culture Media, Conditioned | 1 | 2008 | 110 | 0.020 |
Why?
| | Caspase 3 | 1 | 2008 | 246 | 0.020 |
Why?
| | Endothelium, Vascular | 1 | 2013 | 927 | 0.020 |
Why?
| | T-Cell Antigen Receptor Specificity | 1 | 2006 | 50 | 0.020 |
Why?
| | Fluorides | 1 | 2006 | 49 | 0.020 |
Why?
| | Polyurethanes | 1 | 2006 | 38 | 0.020 |
Why?
| | gag Gene Products, Human Immunodeficiency Virus | 1 | 2006 | 11 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2008 | 767 | 0.020 |
Why?
| | Methacrylates | 1 | 2006 | 117 | 0.020 |
Why?
| | Risk Assessment | 1 | 2015 | 3461 | 0.010 |
Why?
| | Computer Simulation | 1 | 2010 | 982 | 0.010 |
Why?
| | Sequence Alignment | 1 | 2006 | 343 | 0.010 |
Why?
| | Alleles | 1 | 2007 | 892 | 0.010 |
Why?
| | Carrier Proteins | 1 | 2008 | 771 | 0.010 |
Why?
| | Guanosine Tetraphosphate | 1 | 1983 | 5 | 0.010 |
Why?
| | Light | 2 | 1983 | 381 | 0.010 |
Why?
| | Cerulenin | 1 | 1983 | 1 | 0.010 |
Why?
| | Linolenic Acids | 1 | 1983 | 1 | 0.010 |
Why?
| | Linoleic Acids | 1 | 1983 | 7 | 0.010 |
Why?
| | Oleic Acids | 1 | 1983 | 11 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2011 | 2836 | 0.010 |
Why?
| | Oleic Acid | 1 | 1983 | 40 | 0.010 |
Why?
| | Linoleic Acid | 1 | 1983 | 43 | 0.010 |
Why?
| | Nucleotides | 1 | 1983 | 125 | 0.010 |
Why?
| | Fatty Acids, Unsaturated | 1 | 1983 | 99 | 0.010 |
Why?
| | Models, Biological | 1 | 2010 | 1783 | 0.010 |
Why?
| | Membrane Lipids | 1 | 1983 | 91 | 0.010 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2001 | 41 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2013 | 7637 | 0.010 |
Why?
| | Bacteriological Techniques | 1 | 1981 | 73 | 0.010 |
Why?
| | Cardiac Catheterization | 1 | 2003 | 530 | 0.010 |
Why?
| | Apoptosis | 1 | 2008 | 2553 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2003 | 1738 | 0.010 |
Why?
| | HIV Seronegativity | 1 | 1998 | 28 | 0.010 |
Why?
| | Infant | 1 | 2012 | 9482 | 0.010 |
Why?
| | Prognosis | 1 | 2006 | 4039 | 0.010 |
Why?
| | Substance Abuse, Intravenous | 1 | 1998 | 115 | 0.010 |
Why?
| | Antipyrine | 1 | 1996 | 3 | 0.010 |
Why?
| | Drug Resistance, Microbial | 1 | 1996 | 71 | 0.010 |
Why?
| | Drug Interactions | 1 | 1996 | 410 | 0.010 |
Why?
| | Cross-Over Studies | 1 | 1996 | 564 | 0.010 |
Why?
| | Intracellular Membranes | 1 | 1981 | 84 | 0.000 |
Why?
| | Cell Division | 1 | 1981 | 794 | 0.000 |
Why?
|
|
Campbell's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|